Hadassah

ALS Stem Cell Trial Yielding “Impressively Positive” Findings

Thursday, Jan 2 2014

Commenting on the Phase IIa trial of NurOwn™--BrainStorm Cell Therapeutics' stem cell therapy for amyotrophic lateral sclerosis (ALS)--which is being conducted at the Hadassah Medical Organization, Prof. Dimitrios Karussis, principal investigator, reports that the safety data are "impressively positive" and that the "initial indications of clinical efficacy" are cause for optimism regarding the management of ALS and the future of cell therapies for neurodegenerative diseases in general.

Prof. Karussis, Neurologist and Director of the Multiple Sclerosis Center at Hadassah, presented some of his preliminary findings from this ongoing dose-escalating trial at the 24th International Symposium on ALS/MND in Milan, Italy. MND, Motor Neuron Disease, is the name given to a group of diseases in which the nerve cells (neurons) that control muscles undergo degeneration and die.

According to Prof. Karussis, although the final data are not yet available for publication because the trial is still ongoing, researchers have met with only minimal and transient adverse effects, even though the patients in the study were given the treatment both intrathecally (into the cerebrospinal fluid by injection into the subarachnoid space of the spinal cord) and intramuscularly, with up to double the dose of the stem cells given in the Phase I trial.

At the conclusion of the clinical trial, BrainStorm will release the complete set of data and corresponding analyses.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Aug 17 2018

Hadassah Mourns the Loss of Aretha Franklin and Urges Greater Awareness of Diagnosis and Treatment of Pancreatic Cancer

Sadly, the “queen of soul” Aretha Franklin passed away yesterday at age 76, due to an advanced pancreatic neuroendocrine tumor (pancreatic NET or PNET).

READ MORE ›
alt_text

Wednesday, Aug 15 2018

Hadassah Hospital’s Bone Marrow Transplant Department Receives International Acclaim

In a first for Israel, Hadassah Medical Organization’s Bone Marrow Transplantation and Cancer Immunotherapy Department has recently received full accreditation by the Joint Accreditation Committee ISCT-EUROPE & EBMT (JACIE), Europe’s only official accreditation body in the field.

READ MORE ›
alt_text

Tuesday, Aug 14 2018

Hadassah Hospital Helps Educate Mikvah Attendants To Bolster Women’s Health

After a woman emerges from the ritual bath (mikveh) and wraps herself in a towel, says mikveh attendant Daniella Salomon, “I keep an eye out” for anything unusual.

READ MORE ›
alt_text

Tuesday, Aug 7 2018

American Medical Attaché and Consulate Nurse Tour Hadassah Hospital Ein Kerem

Jennifer Kmiecinski, Medical Attaché to the Consulate General of the United States in Israel, visited Hadassah Hospital Ein Kerem earlier this month to assess the level of health care available to American personnel serving in Israel.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More